1 Amarin Co. plc Analyst Ratings, Earnings, Dividends and Insider Trades | $AMRN | NASDAQ:AMRN | Analyst Ratings Network Follow @RatingsNetwork Find a Company: Login Stock Ratings Today's Ratings U.S. Analyst Ratings (NYSE and NASDAQ) All U.S. Ratings Upgrades Downgrades New Coverage Price Target Changes Rating Reiterations Canadian Analyst Ratings (TSE and TSV) U.K. Analyst Ratings (LSE) Australian Analyst Ratings (ASX) Lookup Company Ratings Free Ratings Newsletter ARN Daily Premium ($) RatingsDB ($) Stock Ratings App Earnings Today's Announcements Tomorrow's Announcements Free Earnings Newsletter CER Wire Premium ($) Lookup Company Earnings Dividends Insider Trades About Contact Amarin Co. plc Company Profile (NASDAQ:AMRN) Tweet Analyst RatingsEarningsDividendsInsider TradesCompany ProfileSocial ActivityToday's Chart Consensus Ratings for Amarin Co. plc (NASDAQ:AMRN) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.Ratings Breakdown: 11 Hold Rating(s), 4 Buy Rating(s)Consensus Rating:Hold (Score: 2.27)Consensus Price Target: $5.11 (173.40% upside) Analysts' Ratings History for Amarin Co. plc (NASDAQ:AMRN) Show: All Ratings For This Stock Only the Most Recent Rating From Each Brokerage DateFirmActionRatingPrice TargetDetailsShare2/28/2014AegisReiterated RatingHoldView 2/24/2014MKM PartnersLower Price TargetNeutral$2.50 -> $1.75View 1/16/2014MKM PartnersDowngradeBuy -> Neutral$2.50View 11/19/2013Canaccord GenuityReiterated RatingHold$1.60View 11/19/2013Roth CapitalLower Price TargetBuy$5.00 -> $4.00View 11/11/2013AegisReiterated RatingHoldView 11/8/2013Canaccord GenuityLower Price TargetHold$3.00 -> $1.60View 11/8/2013MKM PartnersLower Price TargetBuy$5.00 -> $2.50View 11/8/2013Citigroup Inc.UpgradeNeutral -> Buy$1.36 -> $2.50View 10/30/2013AegisReiterated RatingHoldView 10/30/2013Leerink SwannDowngradeOutperform -> Market Perform$6.00 -> $2.00View 10/30/2013FBR Capital MarketsInitiated CoverageMarket Perform$2.00View 10/18/2013Citigroup Inc.DowngradeNeutralView 10/18/2013Citigroup Inc.DowngradeBuy -> Neutral$11.00 -> $2.50View 10/17/2013Roth CapitalLower Price TargetBuy$15.00 -> $5.00View 10/17/2013MKM PartnersLower Price TargetBuy$9.00 -> $5.00View 10/17/2013HC WainwrightDowngradeBuy -> NeutralView 10/17/2013Canaccord GenuityDowngradeBuy -> Hold$10.00 -> $3.00View 10/17/2013Jefferies GroupDowngradeBuy$20.00 -> $4.00View 10/17/2013JPMorgan Chase & Co.DowngradeOverweight -> NeutralView 10/16/2013Leerink SwannLower Price Target$6.00View 10/16/2013AegisDowngradeBuy -> Hold$30.00View 10/16/2013SunTrustDowngradeBuy -> Neutral$15.00 -> $8.00View 10/14/2013OppenheimerLower Price TargetMarket Perform$7.00 -> $6.00View 10/14/2013AegisReiterated RatingBuy -> Buy$30.00View 10/14/2013Leerink SwannReiterated RatingOutperformView 10/10/2013Jefferies GroupReiterated RatingBuy -> Positive$4.00View 10/9/2013Goldman SachsBoost Price TargetNeutral$3.00 -> $9.00View 9/17/2013Goldman SachsInitiated CoverageNeutralView 9/13/2013JPMorgan Chase & Co.Lower Price TargetOverweight$12.00 -> $11.00View 9/13/2013AegisReiterated RatingBuy$30.00View 9/4/2013SunTrustInitiated CoverageBuyView 8/12/2013Citigroup Inc.Reiterated RatingBuy$13.00 -> $11.00View 8/9/2013MKM PartnersLower Price TargetBuy$12.00 -> $9.00View 8/9/2013Canaccord GenuityLower Price TargetBuy$17.00 -> $10.00View 8/9/2013Leerink SwannReiterated RatingOutperform$18.00View 8/9/2013Jefferies GroupLower Price TargetBuy$24.00 -> $20.00View 7/24/2013JPMorgan Chase & Co.Lower Price TargetOverweight$18.00 -> $12.00View 7/9/2013OppenheimerLower Price TargetMarket Perform$8.00 -> $7.00View 6/21/2013AegisReiterated RatingBuy -> PositiveView 6/20/2013OppenheimerInitiated CoverageMarket Perform$8.00View 5/20/2013MKM PartnersReiterated RatingBuy$12.00View 5/10/2013Lazard Ltd.Boost Price TargetBuy$11.00 -> $12.00View 5/10/2013MKM PartnersReiterated RatingBuy$12.00View 5/9/2013Leerink SwannReiterated RatingOutperformView 4/25/2013Lazard Ltd.Lower Price TargetBuy$13.00 -> $11.00View 4/2/2013MKM PartnersReiterated RatingBuy$12.00View 3/20/2013Chardan CapitalInitiated CoverageNeutral$8.50View 3/6/2013Roth CapitalLower Price TargetBuy$17.00 -> $16.00View 3/1/2013AegisReiterated RatingBuy$35.00View 1/8/2013Jefferies GroupLower Price TargetBuy$26.00View 12/28/2012JPMorgan Chase & Co.Lower Price TargetOverweight$20.00 -> $18.00View 12/18/2012WedbushSet Price Target$15.00 -> $10.00View 12/11/2012JPMorgan Chase & Co.Reiterated RatingOverweightView 12/7/2012AegisBoost Price TargetBuy$25.00 -> $35.00View 12/7/2012Lazard Ltd.Lower Price Target$16.00View 12/7/2012Canaccord GenuitySet Price TargetBuy$26.00 -> $19.00View 12/7/2012WedbushReiterated RatingNeutralView 12/7/2012Jefferies GroupReiterated RatingBuy$28.00View 12/6/2012Citigroup Inc.Initiated CoverageBuy$20.00View 11/27/2012Citigroup Inc.Initiated CoverageBuy$20.00View 11/26/2012WedbushReiterated RatingNeutralView 11/21/2012Leerink SwannReiterated RatingOutperformView 11/19/2012Jefferies GroupReiterated RatingBuy$28.00View 11/9/2012Jefferies GroupReiterated RatingBuy$28.00View 10/9/2012Roth CapitalReiterated RatingBuyView 10/5/2012Canaccord GenuityReiterated RatingBuy$26.00View 10/3/2012WedbushDowngradeOutperform -> NeutralView 9/12/2012Jefferies GroupReiterated RatingBuyView 9/11/2012Leerink SwannReiterated RatingOutperformView 9/11/2012Canaccord GenuityReiterated RatingBuy -> Buy$26.00View 9/5/2012MKM PartnersReiterated RatingBuyView 9/4/2012Jefferies GroupReiterated RatingBuyView 8/21/2012JPMorgan Chase & Co.Reiterated RatingOverweightView 8/20/2012MKM PartnersReiterated RatingBuyView 8/20/2012Jefferies GroupReiterated RatingBuyView 8/9/2012Jefferies GroupReiterated RatingBuyView 8/9/2012Canaccord GenuityReiterated RatingBuy$27.00 -> $26.00View 7/27/2012Canaccord GenuityReiterated RatingBuyView 7/27/2012Leerink SwannReiterated RatingOutperformView 7/26/2012Jefferies GroupBoost Price Target$26.00 -> $28.00View 7/20/2012MKM PartnersReiterated RatingBuyView 7/19/2012Jefferies GroupReiterated RatingBuyView 7/12/2012MKM PartnersReiterated RatingBuyView 7/9/2012AegisInitiated CoverageBuy$25.00View 6/27/2012Jefferies GroupReiterated RatingBuy$24.00 -> $26.00View 6/11/2012Canaccord GenuityReiterated RatingBuyView 5/9/2012Canaccord GenuityReiterated RatingBuyView 4/30/2012Citigroup Inc.Initiated CoverageBuy$20.00View 4/20/2012JPMorgan Chase & Co.Initiated CoverageOverweight$22.00View 3/28/2012Jefferies GroupReiterated RatingBuy -> PositiveView 3/28/2012Canaccord GenuityReiterated RatingBuyView 3/19/2012Jefferies GroupLower Price Target$24.00View 3/13/2012Canaccord GenuityReiterated RatingBuyView (Data available from 3/12/2012 forward) Earnings History for Amarin Co. plc (NASDAQ:AMRN)DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetailsShare2/27/2014Q413($0.23)($0.26)$11.17 million$10.10 millionViewN/AView 11/7/2013($0.32)($0.25)$10.25 million$8.40 millionViewN/AView 8/8/2013Q2 2013($0.38)($0.26)$5.50 millionViewN/AView 5/9/2013Q1 2013($0.39)($0.41)$5.21 million$2.34 millionViewN/AView 2/28/2013Q4 2012($0.28)($0.28)ViewN/AView 11/8/2012Q312($0.22)($0.26)ViewN/AView (Data available from 1/1/2011 forward) Dividend History for Amarin Co. plc (NASDAQ:AMRN)No dividend announcements for this company have been tracked by Analyst Ratings Network Insider Trading History for Amarin Co. plc (NASDAQ:AMRN)No insider trades for this company have been tracked by Analyst Ratings Network About Amarin Co. plc Amarin Corporation plc (Amarin) is a late-stage biopharmaceutical -company with expertise in lipid science focused on the treatment of cardiovascular disease. The Company's product candidate is AMR101, an ultra-pure omega-3 fatty acid. It is developing AMR101 for the treatment of patients with high triglyceride levels, or hypertriglyceridemia. In September 2011, it filed a New Drug Application (NDA), with the United States Food and Drug Administration (FDA). In December 2011, it commenced patient dosing in its cardiovascular outcomes study of AMR101, titled REDUCE-IT (Reduction of Cardiovascular Events with eicosapentanoic acid (EPA) - Intervention Trial). Headlines: (2/27) Amarin Reports Fourth Quarter and Year-End 2013 Financial Results and Provides Update on Operations Industry, Sector and Symbol: Sector: Healthcare Industry: N/A Sub-Industry: N/A Exchange: NASDAQ Symbol: AMRN CUSIP: Key Metrics: Previous Close: $1.8250 Day Moving Average: $1.7871200 Day Moving Average: $3.1293 P/E Ratio: N/AP/E Growth: N/AMarket Cap: $322.9MCurrent Quarter EPS Consensus Estimate: $-0.64 EPS Additional Links: View AMRN on Google FinanceView AMRN on Yahoo FinanceView AMRN's Company Profile on ReutersSearch for Amarin Co. plc on Google Amarin Co. plc (NASDAQ:AMRN) Chart for Wednesday, March, 12, 2014 (Chart Provided by Yahoo Finance) © Analyst Ratings Network 2010-2014. All rights reserved. Contact | Terms and Conditions | Subscribe | Subscribe Earnings | Google+ Analyst Ratings Network does not provide financial advice and does not issue recommendations or offers to buy or sell any security. Learn more.